- A2 Biotherapeutics Presents Updated Safety and Efficacy Data from EVEREST-2 and DENALI-1 Clinical Studies
- Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment
- Akamis Bio Presents Data from a Phase 1 Study of NG-348 in Patients with Advanced Epithelial Tumors
- Aulos Bioscience’s Imneskibart Demonstrates Outstanding Phase 2 Activity in Checkpoint Inhibitor-Refractory Melanoma and Lung Cancer, Comparing Favorably With Historical Treatment Benchmarks
- Combinations of iOnctura’s roginolisib revert immune suppression in immunotherapy-resistant NSCLC
- Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
- Indapta Therapeutics Presents Data Demonstrating Clinical Activity of its Allogeneic Natural Killer Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma
- Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
- KaliVir Immunotherapeutics Reports 71% Objective Response Rate in Patients with Advanced, Cutaneous Malignancies in Phase 1/1b STEALTH-001 Trial
- Marengo Presents Interim Phase 2 STARt-002 Results for First-in-Class Selective T-Cell Agonist Invikafusp Alfa Plus Sacituzumab Govitecan Across Two Metastatic Breast Cancer Cohorts
- MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance
- New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
- Obsidian Therapeutics Presents Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma
- Onchilles Pharma Reports First Clinical Data That N17350 Could Turn One Tumor into a Personalized Cancer Vaccine
- OncoC4 Reports Encouraging Phase 1/2 Data for Cesalatamig Monotherapy in Previously Treated NSCLC
- Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients
- Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data
- SOTIO Presents Initial Data from VICTORIA-01 Phase 1 Clinical Study of Immunocytokine SOT201
- Strand Therapeutics Presents Updated STX-001 Clinical Data Highlighting Durable, Systemic Anti-Tumor Activity, and Showcase STX-003 Trial Design
- Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
- Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented